Profiles CDx - Cancer Confirmation Diagnosis

Non-invasive and disruptive Evidence Based Laboratory Medicine (EBLM) tests that are designed to aid in the diagnostic evaluation by confirming or ruling out the presence of malignancies, focusing on assessing cancer based on prior images or suspicious findings.

All Venient CDx confirmation diagnosis tests are exclusively based on routine blood and urine tests, which powered by our own Machine Learning algorithms (ML), provide unprecedented rates of accuracy.

These tests are focused on aiding doctors and general practitioners (GPs) in diagnostic evaluation, confirming, or ruling out the presence of malignancies based on previous images or suspicious findings —e.g., suspicious findings from mammography for breast cancer, a thoracic X-ray or computed tomography (CT) scan for lung cancer, a prostate-specific antigen (PSA) result higher than 4 ng/mL for prostate cancer, or an enlarged prostate detected by digital rectal examination (DRE)—. They are also based in the Barcelona Criteria, which were proposed by the Spanish Society of Laboratory Medicine (SEQCML) in 1994 and further reviewed in 2024, for the correct interpretation of serum tumor markers (TM) in order to detect and avoid false positive (FP) results.

These tests are exclusively for use by doctors and GPs. Rx only.